regulatory
confidence high
sentiment positive
materiality 0.70
Cartesian Therapeutics receives FDA RMAT designation for Descartes-08 in myasthenia gravis
Cartesian Therapeutics, Inc.
- FDA granted RMAT designation for Descartes-08, an autologous mRNA CAR-T therapy targeting BCMA for myasthenia gravis.
- RMAT designation provides fast track and breakthrough therapy benefits, enabling expedited FDA interactions and development.
- Topline data from Phase 2b randomized, double-blind, placebo-controlled trial of Descartes-08 in MG expected mid-2024.
- Descartes-08 previously received FDA Orphan Drug Designation for MG.
- Phase 2a data (Jan 2024) showed durable autoantibody depletion and clinically meaningful MG severity score improvements over 12 months.